NO20084785L - Benzimidazol 5-slfonamidderivater som cannabinoid 1(CB1) reseptorligander - Google Patents

Benzimidazol 5-slfonamidderivater som cannabinoid 1(CB1) reseptorligander

Info

Publication number
NO20084785L
NO20084785L NO20084785A NO20084785A NO20084785L NO 20084785 L NO20084785 L NO 20084785L NO 20084785 A NO20084785 A NO 20084785A NO 20084785 A NO20084785 A NO 20084785A NO 20084785 L NO20084785 L NO 20084785L
Authority
NO
Norway
Prior art keywords
cannabinoid
benzimidazole
receptor ligands
sulfonamide derivatives
sulfonamide
Prior art date
Application number
NO20084785A
Other languages
English (en)
Norwegian (no)
Inventor
Christopher Walpole
Zhong-Yong Wei
Ziping Liu
Maxime Tremblay
William Brown
Sanjay Srivastava
Daniel Page
Zena Qadoumi
Hua Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20084785L publication Critical patent/NO20084785L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20084785A 2006-04-18 2008-11-12 Benzimidazol 5-slfonamidderivater som cannabinoid 1(CB1) reseptorligander NO20084785L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74501106P 2006-04-18 2006-04-18
PCT/SE2007/000359 WO2007120101A1 (en) 2006-04-18 2007-04-17 Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands

Publications (1)

Publication Number Publication Date
NO20084785L true NO20084785L (no) 2009-01-09

Family

ID=38609783

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084785A NO20084785L (no) 2006-04-18 2008-11-12 Benzimidazol 5-slfonamidderivater som cannabinoid 1(CB1) reseptorligander

Country Status (19)

Country Link
US (1) US7615642B2 (pt)
EP (1) EP2010526A4 (pt)
JP (1) JP2009534379A (pt)
KR (1) KR20080109936A (pt)
CN (1) CN101472917A (pt)
AR (1) AR060472A1 (pt)
AU (1) AU2007239102B8 (pt)
BR (1) BRPI0709625A2 (pt)
CA (1) CA2649287A1 (pt)
CO (1) CO6140035A2 (pt)
EC (1) ECSP088829A (pt)
IL (1) IL194393A0 (pt)
MX (1) MX2008013040A (pt)
NO (1) NO20084785L (pt)
RU (1) RU2008139479A (pt)
TW (1) TW200808769A (pt)
UY (1) UY30289A1 (pt)
WO (1) WO2007120101A1 (pt)
ZA (1) ZA200808692B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1797077B1 (en) * 2004-09-24 2012-02-15 AstraZeneca AB Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
ATE459352T1 (de) * 2006-07-04 2010-03-15 Janssen Pharmaceutica Nv Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP5756800B2 (ja) * 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
EP2456310A4 (en) * 2009-07-23 2013-01-23 Univ Vanderbilt SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
CN104140427A (zh) * 2014-07-05 2014-11-12 湖南华腾制药有限公司 一种四氢吡唑并[1,5-a]嘧啶的制备方法
FR3030516B1 (fr) * 2014-12-19 2019-12-27 Galderma Research & Development Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
EP3814337B1 (en) * 2018-06-27 2025-05-14 F. Hoffmann-La Roche AG Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB955961A (en) * 1959-09-24 1964-04-22 Gevaert Photo Prod Nv Benzimidazole derivatives
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (pt) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
WO1997024334A1 (en) 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CZ2002959A3 (cs) 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitory faktoru Xa
US7115645B2 (en) 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
EE05515B1 (et) 2000-01-14 2012-02-15 Schering@Aktiengesellschaft 1 2 diarlbensimidasoolid mikrogliia aktivatsiooniga seotud haiguste raviks
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
SE0301699D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005007625A2 (en) 2003-07-14 2005-01-27 The University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20060035884A1 (en) 2004-05-20 2006-02-16 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2006009876A2 (en) 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
CA2573426C (en) 2004-07-30 2015-11-17 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
US20060052421A1 (en) 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
JP2008514591A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用
AU2005287427B2 (en) 2004-09-24 2009-03-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof I
EP1794150A1 (en) 2004-09-24 2007-06-13 AstraZeneca AB Benzimidazole derivatives and their use as cannabinoid receptor ligands I
EP1797077B1 (en) 2004-09-24 2012-02-15 AstraZeneca AB Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
JP2008514589A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それらを含有する組成物、それらの製造及びそれらの使用ｉｉｉｉ
CA2582507A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
JP2008514590A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用
WO2006033633A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparations thereof and uses thereof ii
ES2318556T3 (es) 2004-11-02 2009-05-01 Pfizer, Inc. Derivados de sulfonil bencimidazol.
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
UY30289A1 (es) 2007-11-30
TW200808769A (en) 2008-02-16
AU2007239102B8 (en) 2011-08-11
JP2009534379A (ja) 2009-09-24
CA2649287A1 (en) 2007-10-25
ZA200808692B (en) 2009-07-29
US20070244092A1 (en) 2007-10-18
WO2007120101A1 (en) 2007-10-25
AU2007239102A1 (en) 2007-10-25
RU2008139479A (ru) 2010-05-27
AU2007239102B2 (en) 2011-07-07
CO6140035A2 (es) 2010-03-19
EP2010526A4 (en) 2011-06-22
US7615642B2 (en) 2009-11-10
EP2010526A1 (en) 2009-01-07
AR060472A1 (es) 2008-06-18
BRPI0709625A2 (pt) 2011-07-19
MX2008013040A (es) 2008-10-17
CN101472917A (zh) 2009-07-01
ECSP088829A (es) 2008-11-27
KR20080109936A (ko) 2008-12-17
IL194393A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
NO20084785L (no) Benzimidazol 5-slfonamidderivater som cannabinoid 1(CB1) reseptorligander
LTPA2020528I1 (lt) Benzimidazolo dariniai
EP2157859A4 (en) INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
EP2091329A4 (en) Indazole CONNECTIONS
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
DK2206710T3 (da) Indolderivater som s1p1-receptor agonister
ATE526325T1 (de) Substituierte benzimidazole als kinaseinhibitoren
DK2029549T3 (da) Phenyl-pyrazol-derivater som ikke-steroide glucocoricoid-receptorligander
DE602007006531D1 (de) Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
EP2088861A4 (en) Benzimidazole compounds
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
ATE482201T1 (de) Vr1-benzimidazolmodulatoren
EP1981215A4 (en) NETWORK SYSTEM
ATE494290T1 (de) Substituierte 2,5-dihydro-3h-pyrazol-ä4,3-cü- pyridazin-3-on-derivate, ihre herstellung und ihre verwendung als cannibinoid-cb1- rezeptorliganden
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
ZA200903075B (en) Bridged bicyclic indazoles as cannabinoid receptor ligands
BRPI0821315A2 (pt) compostos benzimidazol
ATE522517T1 (de) Neue imidazolderivate
NL1030324A1 (nl) Sulfonylbenzimidazoolderivaten.
DK2000920T3 (da) Netværkssystem
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
IL189390A0 (en) (indol-3-yl)heterocycle derivatives as agonists of the cannabinoid cb1 receptor
DK2148873T3 (da) 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
DK2099784T3 (da) 1,5-diphenyl-3-pyridinylamino-1,5-dihydrioyrrolidin-2-on som cb1-receptor-modulatorer
ATE524457T1 (de) Neue imidazolderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application